Hero Background

PROVIDERS /// ONCOLOGY

Creating more options for your patients

Our collection of offerings uncover unique insights that empower you to customize treatment for individual patients, throughout their cancer journey.

CONTACT us

Streamlining your workflow

One order. One platform. One financial assistance program.

Browse our FAQs
Working with the top hospitals in North America

In the rapidly changing world of cancer care and precision medicine, Tempus is the established leader. They provide rapid, accurate results while also continuing to develop innovative strategies to improve patient outcomes. With a focus on both clearly defining actionable mutations and extending treatment options by matching specific patients to specific local and national studies, Tempus is directly changing the patients' lives.

Joseph K Hofmeister, MD, OhioHealth

Working with the top hospitals in North America

Breast cancer care has involved use of biomarkers for years in order to determine appropriate therapy. Genomic information has now been added to the list of crucial biomarkers needed to know how to treat metastatic breast cancer patients with the approval of targeted therapy for BRCA and PIK3CA mutations. Having this information also gives a patient the best opportunity to consider one of numerous biomarker driven clinical trials. These options allow as personalized an approach to treatment as possible and I have no doubt that genomic data will continue to transform the way patients are treated as our field moves forward.

Megan Kruse, MD, Cleveland Clinic

  • 4K+

    oncologists rely on Tempus as their precision medicine partner

  • 12K+

    patients identified for potential enrollment into clinical trials

  • 5M+

    de-identified research records

  • 20+

    operational countries across North, Central, South America, Europe, Middle East, and Asia

Our Science

view all publications
  • UPCOMING WEBINAR:

    Operational Metrics for the ELAINE II Study Combining a Traditional Approach With A Just-in-Time Model

    This study demonstrates the success that Tempus’ TIME Trial Program had with Sermonix’s Elaine II trial for patients with ESR1-mutant, estrogen receptor (ER)–positive, HER2-negative metastatic breast cancer.

    Read more
  • UPCOMING WEBINAR:

    Use Of Clinical RNA-Sequencing In the Detection of Actionable Fusions Compared To DNA-Sequencing Alone

    RNA-based, whole-exome sequencing provides a complementary method for fusion detection, and may improve the identification of actionable variants.

    Read more
  • UPCOMING WEBINAR:

    Dual Tissue and Plasma Testing Improves Detection of Actionable Variants in Patients With Solid Cancers

    Dual tissue and ctDNA testing, “dual testing”, improved identification of actionable variants compared with either modality alone.

    Read more
  • UPCOMING WEBINAR:

    Nature Biotechnology Study Reveals that Tempus’ xT Platform Increases Cancer Patients’ Personalized Therapeutic Opportunities

    Extensive molecular profiling combined with clinical data identifies targeted therapies and clinical trials for a large proportion of cancer patients, and paired tumor/normal plus transcriptome sequencing outperforms tumor-only DNA panel testing.

    Read more
  • UPCOMING WEBINAR:

    Validation of a Liquid Biopsy Assay with Molecular and Clinical Profiling of Circulating Tumor DNA

    Actionable variants would have been missed if only solid tumor or liquid biopsy tests were performed. Thus, we believe that liquid biopsies provide value to patients when used in combination with standard tissue genotyping.

    Read more
  • UPCOMING WEBINAR:

    Prevalence of Germline Findings Among Tumors From Cancer Types Lacking Hereditary Testing Guidelines

    This study found that Tumor-normal (T/N) matched next-generation sequencing (NGS) has multiple advantages including enhanced variant classification and incidental germline variant discovery that may be missed with a guidelines-based approach.

    Read more

Featured News and Events

view all news
  • UPCOMING WEBINAR:

    Tempus announces research collaboration with Intermountain Healthcare

    The partnership will provide increased accessibility to Tempus’ multimodal datasets to further enhance Intermountain’s research program.

    Read more
  • UPCOMING WEBINAR:

    Tempus provides access to Lilly Lung Cancer NGS Program for eligible mNSCLC patients

    The Lilly Lung Cancer NGS Testing Program provides access to solid tumor and liquid biopsy comprehensive genomic sequencing at no cost for eligible mNSCLC patients.

    Read more
  • UPCOMING WEBINAR:

    Tempus announces multi-year agreement with the VA NPOP

    Tempus and the U.S. Department of Veterans Affairs (VA) National Precision Oncology Program (NPOP) will expand access to genomic testing and deliver personalized medicine for veterans with cancer.

    Read more
  • UPCOMING WEBINAR:

    Eric Lefkofsky joins the Washington Post’s “Chasing Cancer” series

    Tempus founder and CEO Eric Lefkofsky discusses the state of precision medicine with reporter Yasmeen Abutaleb.

    Read more
  • UPCOMING WEBINAR:

    Tempus introduces the DPYD predictive diagnostic test to its growing collection of algorithms

    The newest Tempus algorithmic predictive test assesses for relevant mutations in the DPYD gene and helps physicians better identify patients at potential risk for toxicity to certain chemotherapies.

    Read more
  • UPCOMING WEBINAR:

    Tempus and Cedars-Sinai collaborate on a new precision medicine initiative

    As part of the collaboration, Cedars-Sinai is leveraging Tempus’ genomic sequencing tests and data structuring capabilities for a variety of clinical and research efforts.

    Read more

Validations and Resources

view all resources
  • UPCOMING WEBINAR:

    Tempus xT Validation

    Our Tempus xT assay is designed to detect actionable oncologic targets by sequencing tumor samples with matched normal saliva or blood samples, when available.

    Read more
  • UPCOMING WEBINAR:

    Tempus xF Validation

    Our non-invasive Tempus xF liquid biopsy assay detects cell-free DNA (cfDNA) in blood specimens of advanced solid tumor patients.

    Read more
  • UPCOMING WEBINAR:

    Standard Requisition Form

    We offer an easy ordering process which allows you to order any of somatic and germline panels along with our add-on tests like HRD, TO and DPYD.

    View here

Partnering with Tempus is investing in the future

Every new test and data point strengthens our algorithms, predictions, and recommendations to improve treatment options for future patients.